Total trials
680
Active
142
Phase 3
20
Total enrollment
184,907
Pipeline matrix
Showing 31 of 31 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dual versus triple therapy in treatment of HIV-1 infection. | — | — | — | — | — | 1 | |
| Proactive TDM-based dosing of secukinumab | — | — | — | — | — | 1 | |
| Proactive TDM-based dosing of ixekizumab | — | — | — | — | — | 1 | |
| Proactive TDM-based dosing of guselkumab | — | — | — | — | — | 1 | |
| Elonva® | — | — | — | — | — | 1 | |
| Puregon® | — | — | — | — | — | 1 | |
| Orgalutran® | — | — | — | — | — | 1 | |
| Gonapeptyl® | — | — | — | — | — | 1 | |
| Cerazette® | — | — | — | — | — | 1 | |
| Estrogen | — | — | — | — | — | 1 | |
| dehydroepiandrosterone | — | — | — | — | — | 1 | |
| Estrogen + probiotics | — | — | — | — | — | 1 | |
| Moisturizer | — | — | — | — | — | 1 | |
| Beta-lactam antibiotic | — | — | — | — | — | 1 | |
| Allogenic FMT | — | — | — | — | — | 1 | |
| Autologous FMT | — | — | — | — | — | 1 | |
| week 24 | — | — | — | — | — | 1 | |
| week 36 | — | — | — | — | — | 1 | |
| Week 48 | — | — | — | — | — | 1 | |
| Week 60 | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 1 | |
| androgen deprivation therapy | — | — | — | — | — | 1 | |
| Immunotherapy | — | — | — | — | — | 1 | |
| PIPAC with Nal-IRI | — | — | — | — | — | 1 | |
| Dupilumab | — | — | — | — | — | 1 | |
| Early combination anti-retroviral treatment | — | — | — | — | — | 1 | |
| Mepolizumab | — | — | — | — | — | 1 | |
| blood sampling | — | — | — | — | — | 1 | |
| Cefazolin | — | — | — | — | — | 1 | |
| Paracetamol | — | — | — | — | — | 1 | |
| Hormonal substitution therapy per SOC | — | — | — | — | — | 1 |
Next readouts
- 2023-04-30
- 2025-05-31
- 2025-12-30
- 2026-03
- 2026-03-02
- 2026-06-30
- 2026-08-01
- 2027-01-30
- 2027-10-01
- 2027-12
Top conditions
- Prostate Cancer13
- Epilepsy12
- Stroke12
- Psoriasis Vulgaris9
- Nocturia8
- Dental Implants8
- Healthy7
- Colorectal Cancer7
Frequently asked questions about University Hospital, Ghent
- How many clinical trials does University Hospital, Ghent have on ClinicalTrials.gov?
- University Hospital, Ghent is listed as the lead sponsor on 680 clinical trials in ClinicalTrials.gov, 142 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Ghent's trials are in Phase 3?
- 20 of University Hospital, Ghent's trials are in Phase 3, spread across 31 active drug programs.
- What therapeutic areas does University Hospital, Ghent focus on?
- University Hospital, Ghent's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Epilepsy, Stroke, Psoriasis Vulgaris, Nocturia.
- When are University Hospital, Ghent's next clinical trial readouts?
- University Hospital, Ghent has 10 upcoming primary-completion readouts tracked here; the soonest is “PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases”, expected around 2023-04-30.